Company Description

Isoprene Pharmaceuticals is a small molecular degrader company. Their lead development candidate is a FIC MNK1/2 degrader that regulates oncogenic protein translation and is expected to be a monotherapy and used in combination to overcome cancer intrinsic and extrinsic resistance.